) The Automated DNA Sequencing Facility was originally established as a Protein Sequencing Facility in 1974. Later, nucleic acid sequencing supplemented, and then replaced amino acid sequencing. Dr. Richard Hardy assumed direction of the Facility in 1993. Automated sequencing using an ABI Model 373 was set up in 1994. Model 377 sequencers were subsequently added, one in 1995, and another in 1997. The DNA Sequencing Facility provides Fox Chase investigators with computer-readable sequences of their DNA samples in a timely and cost effective manner, generating data more rapidly and of greater read-length compared to manual sequencing. Automated sequence analysis is used by investigators to verify DNA constructs, to identify mutations, and to determine the structure of newly cloned genes. Sequencing large genes (5-20 Kb) is much more tractable using automated sequence analysis, generating results in a few weeks, as compared to months using manual sequencing. The volume of usage of the Facility has increased strikingly over the past five years from 5,000 sequences in 1994 to over 17,000 in 1998. In addition to sequencing, analysis of DNA polymorphisms, important in genetic mapping studies, is also available in the Facility using """"""""GeneScan"""""""" software. Sequencing reactions are done during the day and run overnight. GeneScan runs are performed during the day on the Model 377XL instruments. The Facility is used by 45 peer-review funded investigators (represents 98 percent of the Facility usage) across 13 scientific Programs from all three Divisions. Equitable access to the Facility is assured by a faculty Oversight Committee.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-40
Application #
6652203
Study Section
Project Start
2002-07-01
Project End
2003-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
40
Fiscal Year
2002
Total Cost
$196,218
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Golemis, Erica A; Scheet, Paul; Beck, Tim N et al. (2018) Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32:868-902
Reese, Jennifer Barsky; Sorice, Kristen; Lepore, Stephen J et al. (2018) Patient-clinician communication about sexual health in breast cancer: A mixed-methods analysis of clinic dialogue. Patient Educ Couns :
Wagner, Jessica; Kline, C Leah; Zhou, Lanlan et al. (2018) Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Invest 128:2325-2338
Araiza-Olivera, D; Feng, Y; Semenova, G et al. (2018) Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors. Oncogene 37:944-952
Fareed, Muhammad M; Eldib, Ahmed; Weiss, Stephanie E et al. (2018) A treatment planning comparison between a novel rotating gamma system and robotic linear accelerator based intracranial stereotactic radiosurgery/radiotherapy. Phys Med Biol 63:035029
Bleicher, Richard J (2018) Timing and Delays in Breast Cancer Evaluation and Treatment. Ann Surg Oncol 25:2829-2838
Bai, Tian; Chanda, Ashis Kumar; Egleston, Brian L et al. (2018) EHR phenotyping via jointly embedding medical concepts and words into a unified vector space. BMC Med Inform Decis Mak 18:123
Mehrazin, Reza; Dulaimi, Essel; Uzzo, Robert G et al. (2018) The correlation between gain of chromosome 8q and survival in patients with clear and papillary renal cell carcinoma. Ther Adv Urol 10:3-10
Tang, Baiqing; Lee, Hyung-Ok; An, Serim S et al. (2018) Specific Targeting of MTAP-Deleted Tumors with a Combination of 2'-Fluoroadenine and 5'-Methylthioadenosine. Cancer Res 78:4386-4395
Fang, Carolyn Y; Tseng, Marilyn (2018) Ethnic density and cancer: A review of the evidence. Cancer 124:1877-1903

Showing the most recent 10 out of 1280 publications